Reported 1 day ago
Eli Lilly's stock has seen a significant decline of over 20% due to increasing competition in the obesity drug market and disappointing earnings forecasts. However, Wall Street analysts remain optimistic, with 20 out of 28 recommending the stock as a 'buy' or 'strong buy'. Analysts predict a potential price increase, with targets suggesting an upside of around 19% to nearly 59%. Despite concerns, many believe that Eli Lilly's drug pipeline still holds promise for substantial sales growth.
Source: YAHOO